Amdipharm Mercury, Concordia Healthcare deal

Concordia will acquire fellow generic and pharmaceutical company Amdipharm from private equity firm Cinven for up to $3.6 billion, including debt. The acquisition consists of L800 million ($1.2 billion) in cash and 8.5 million of Concordia shares valued at C$939 million ($707 million), based on the company’s close of C$110.60 on Sept. 4, the last trading day before the deal was announced. Concordia will purchase $1.4 billion of Amdipharm’s debt. Amdipharm is eligible to receive an earn-out payment of up to L144 million ($221 million), payable in cash in 4Q16. The equity represents a 19.9% ownership in Concordia. ...